Recursion Pharmaceuticals quietly shut down work on one of its clinical programs Tuesday. Researchers will end development on REC-3599, a drug candidate for GM2 gangliosidosis, the Salt Lake City biotech said in SEC filings Tuesday. Recursion CEO Chris Gibson told Endpoints News that the move will help the company focus…
News
Waystar Reports Second Quarter 2024 Results
Revenue growth of 20% year-over-year Net loss of $27.7 million and non-GAAP net income of $5.0 million Net loss margin of (11.8)%; Adjusted EBITDA margin of 40% LEHI, Utah and LOUISVILLE, Ky., Aug. 7, 2024 […]
News
Co-Diagnostics, Inc. CEO Delivers Manufacturing and Commercialization Update in Conference Keynote Address
Presentation included announcement of the opening of the new manufacturing facility in Salt Lake City, UT SALT LAKE CITY, March 21, 2024 /PRNewswire/ — Co-Diagnostics, Inc. (Nasdaq: CODX) (the “Company” or “Co-Dx”), a molecular diagnostics […]
News
Employees Spend Up to $1,500 Out of Pocket as Employer Benefits Miss the Mark, Castlight Survey Finds
36% seek their own tools first and nearly half use consumer health apps as static, hard‑to‑navigate benefits fail to keep pace with employee needs SANDY, Utah, April 28, 2026 /PRNewswire/ — Castlight Health, a leader […]
